Value Investor Identifies Nvidia & Novo Nordisk as Potential 2026 Buys (If Prices Are Right)

  entifies-nvidia-novo-nordisk-as-potential-2026-buys-if-prices-are-right.html
  Stocks and Investing on Thu, Jan 01st, 2026 by Seeking Alpha
      Locale: UNITED STATES

Patience is Key: Two Companies Author Believes Will Shine by 2026 – But Only at the Right Price

The investment landscape can feel overwhelming, with constant news cycles and fleeting trends vying for attention. However, successful investing often requires a longer-term vision, a willingness to wait, and a disciplined approach to valuation. In a recent Seeking Alpha article, contributor Mark “Spooner” Darr (known for his value-oriented approach), outlines two companies he’s closely watching with the intention of making significant investments in 2026 – if the prices are right. His strategy emphasizes patience and recognizing that sometimes the best opportunities require waiting for a market correction or company-specific setbacks to create favorable entry points.

Darr's core philosophy is rooted in identifying companies with strong fundamentals, durable competitive advantages ("moats"), and significant potential for future growth, but acknowledging that current valuations may be inflated by short-term exuberance. He’s not chasing the "hot stock" of the moment; he’s building a portfolio for sustained long-term success. The article isn't a buy recommendation now, but rather an articulation of his watchlist and the reasoning behind it, with a clear timeline attached.

The Two Companies on Darr's Radar:

1. Nvidia (NVDA): Riding the Wave of AI – With Caution. Nvidia is arguably the most prominent name in Darr’s analysis. The company has become synonymous with artificial intelligence thanks to its dominance in GPU technology, which is essential for training and deploying AI models. Darr acknowledges Nvidia's current exceptional performance and the transformative potential of generative AI. He highlights that Nvidia isn't just benefiting from AI; they are enabling it. Their chips power everything from cloud computing infrastructure to self-driving cars.

However, Darr’s enthusiasm is tempered by significant valuation concerns. As of the article’s writing (and even more so now), Nvidia trades at a very high price-to-earnings ratio, reflecting immense investor optimism and expectations for continued explosive growth. Darr believes this premium may be unsustainable, especially if competition intensifies or macroeconomic conditions worsen. He points out that while Nvidia has built considerable barriers to entry through its CUDA ecosystem (a proprietary platform for parallel computing), competitors like AMD and Intel are actively working on alternative AI solutions, potentially eroding Nvidia’s market share over time. He sees a potential scenario where a significant correction in the broader market or a company-specific setback could bring Nvidia's price down to a more reasonable level – one that allows for a compelling investment opportunity by 2026. He emphasizes needing to see a substantial pullback, potentially 50% or more from current highs, before considering an entry. (You can read more about Nvidia’s competitive landscape and potential risks in this AMD investor presentation.)

1. Novo Nordisk (NVO): The Reign of Obesity Drugs – A Long-Term Play. Novo Nordisk, a Danish pharmaceutical giant, is Darr's second target. The company has seen phenomenal growth thanks to its groundbreaking GLP-1 receptor agonists like Ozempic and Wegovy, used for treating diabetes and obesity respectively. Darr believes the market is only scratching the surface of this massive opportunity. He highlights that obesity affects a significant portion of the global population and represents an enormous unmet medical need. The potential for further innovation within the GLP-1 class – with drugs targeting even broader health benefits or improved efficacy – is substantial.

While Novo Nordisk’s stock has also experienced considerable appreciation, Darr believes its valuation is somewhat more justified given the company's long runway for growth and strong competitive position. However, he acknowledges risks including potential patent challenges, increased competition from biosimilar manufacturers (drugs that are very similar to innovator drugs but are produced after the original patent expires), and regulatory hurdles. He’s also wary of hype surrounding the GLP-1 class potentially driving unrealistic expectations. Darr anticipates a more gradual appreciation in Novo Nordisk's stock price compared to Nvidia, making it a slightly less demanding entry point – although he still prefers waiting for a pullback before committing significant capital. He expects that even with increased competition, Novo Nordisk’s first-mover advantage and established brand recognition will provide a solid foundation for continued success. (Novo Nordisk's investor relations website provides detailed information on their pipeline and market analysis.)

The Importance of Patience & Valuation:

Darr repeatedly stresses the importance of patience in his investment strategy. He believes that many investors are driven by fear of missing out (FOMO), leading them to overpay for assets. His approach is to remain disciplined, even when others are making substantial profits. He argues that waiting for a price correction – a period where the market re-evaluates a company’s worth – can significantly improve investment returns over the long term.

He also emphasizes the critical role of valuation. Simply identifying good companies isn't enough; investors must buy them at prices that offer a margin of safety, providing a buffer against unforeseen risks and allowing for compounding growth. Darr doesn't specify exact price targets in his article but makes it clear he will only act when valuations align with his long-term expectations.

Conclusion:

Mark "Spooner" Darr’s analysis offers a valuable lesson for investors: successful investing isn't always about timing the market perfectly; it's often about identifying quality companies and having the discipline to wait for the right price. His focus on Nvidia and Novo Nordisk highlights the potential of AI and innovative pharmaceuticals, but his cautionary approach serves as a reminder that even the most promising opportunities require careful consideration and a long-term perspective. While 2026 might seem distant, Darr’s strategy emphasizes preparing now for future investment possibilities by focusing on fundamentals and resisting the temptation to chase short-term gains.

Disclaimer: I am an AI chatbot and cannot provide financial advice. This article is based solely on the provided Seeking Alpha link and should not be considered a recommendation to buy or sell any securities.